Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTOR | P42345 | 11/20 | 0.80 |
| ▸ | PIM1 | P11309 | 5/20 | 0.62 |
| ▸ | PIM2 | Q9P1W9 | 5/20 | 0.62 |
| ▸ | RPTOR | Q8N122 | 4/20 | 0.59 |
| ▸ | MLST8 | Q9BVC4 | 4/20 | 0.59 |
| ▸ | MGAM | O43451 | 2/20 | 0.54 |
| ▸ | GAA | P10253 | 2/20 | 0.54 |
| ▸ | SI | P14410 | 2/20 | 0.54 |
| ▸ | MGAM2 | Q2M2H8 | 2/20 | 0.54 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.47 |
| ▸ | TTR | P02766 | 1/20 | 0.46 |
| ▸ | CISD1 | Q9NZ45 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23036914 | 0.89 | MTOR (1.00) | MTORRPTORMLST8CISD1 | |
| SCHEMBL23036900 | 0.87 | MTOR (0.76) | MTORPIM1PIM2RPTORMLST8 | |
| SCHEMBL23036902 | 0.86 | MTOR (0.78) | MTORPIM1PIM2RPTORMLST8 | |
| SCHEMBL23036919 | 0.86 | MTOR (1.00) | MTORPIM1PIM2RPTORMLST8 | |
| SCHEMBL30438523 | 0.82 | MTOR (0.74) | MTORPIM1PIM2RPTORMLST8 | |
| SCHEMBL23036940 | 0.82 | MTOR (0.74) | MTORPIM1PIM2RPTORMLST8 | |
| SCHEMBL23036896 | 0.81 | MTOR (1.00) | MTORPIM1PIM2RPTORMLST8 | |
| SCHEMBL23036911 | 0.81 | MTOR (0.69) | MTORPIM1PIM2RPTORMLST8 | |
| SCHEMBL23839859 | 0.80 | MTOR (0.64) | MTORPIM1PIM2RPTORMLST8 | |
| SCHEMBL23036904 | 0.79 | MTOR (0.79) | MTORPIM1PIM2RPTORMLST8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112368279-B | Novel compounds as mTOR inhibitors and uses thereof | 医药生命融合研究团 | 2024-05-28 | — | — | CN | claimed |
| US-11649231-B2 | Compound as mTOR inhibitor and use thereof | MEDICINAL BIOCONVERGENCE RESEARCH CENTER (KR) | 2023-05-16 | — | — | US | claimed |
| US-20210292314-A1 | NOVEL COMPOUND AS mTOR INHIBITOR AND USE THEREOF | MEDICINAL BIOCONVERGENCE RESEARCH CENTER (KR) | 2021-09-23 | — | — | US | claimed |
| EP-3786163-A1 | NOVEL COMPOUND AS MTOR INHIBITOR AND USE THEREOF | Medicinal Bioconvergence Research Center (KR) | 2021-03-03 | — | — | EP | claimed |
| CN-112368279-B | Novel compounds as mTOR inhibitors and uses thereof | 医药生命融合研究团 | 2024-05-28 | — | — | CN | disclosed |
| US-11649231-B2 | Compound as mTOR inhibitor and use thereof | MEDICINAL BIOCONVERGENCE RESEARCH CENTER (KR) | 2023-05-16 | — | — | US | disclosed |
| US-11649231-B2 | Compound as mTOR inhibitor and use thereof | MEDICINAL BIOCONVERGENCE RESEARCH CENTER (KR) | 2023-05-16 | — | — | US | disclosed |
| US-11649231-B2 | Compound as mTOR inhibitor and use thereof | MEDICINAL BIOCONVERGENCE RESEARCH CENTER (KR) | 2023-05-16 | — | — | US | disclosed |
| US-20210292314-A1 | NOVEL COMPOUND AS mTOR INHIBITOR AND USE THEREOF | MEDICINAL BIOCONVERGENCE RESEARCH CENTER (KR) | 2021-09-23 | — | — | US | disclosed |
| US-20210292314-A1 | NOVEL COMPOUND AS mTOR INHIBITOR AND USE THEREOF | MEDICINAL BIOCONVERGENCE RESEARCH CENTER (KR) | 2021-09-23 | — | — | US | disclosed |
| EP-3786163-A1 | NOVEL COMPOUND AS MTOR INHIBITOR AND USE THEREOF | Medicinal Bioconvergence Research Center (KR) | 2021-03-03 | — | — | EP | disclosed |
| CN-112368279-A | Novel compounds as mTOR inhibitors and uses thereof | 医药生命融合研究团 | 2021-02-12 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11649231-B2 | Compound as mTOR inhibitor and use thereof | MTOR, RICTOR, RPTOR | MTOR 1/4885PIM1 385/4885PIM2 656/4885 |
| US-20210292314-A1 | NOVEL COMPOUND AS mTOR INHIBITOR AND USE THEREOF | MTOR, RICTOR, RPTOR | MTOR 1/4885PIM1 345/4885PIM2 577/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.